MARKET

LGND

LGND

Ligand Pharma
NASDAQ
94.64
+0.78
+0.83%
After Hours: 94.64 0 0.00% 16:22 10/05 EDT
OPEN
92.37
PREV CLOSE
93.86
HIGH
95.02
LOW
90.11
VOLUME
147.29K
TURNOVER
0
52 WEEK HIGH
169.98
52 WEEK LOW
72.57
MARKET CAP
1.60B
P/E (TTM)
-192.9066
1D
5D
1M
3M
1Y
5Y
Ligand Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
EMERYVILLE, Calif., October 03, 2022--Ligand Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Business Wire · 2d ago
Ligand Pharmaceuticals Files For Mixed-Securities Shelf Offering, Size Not Disclosed
-Reuters
Benzinga · 5d ago
Ligand Pharmaceuticals Licensor Of Sermonix Pharmaceuticals Shares Details Of Durable Complete Clinical Response In A Metastatic ER+/HER2- Breast Cancer Patient With An ESR1 Mutation After Prior CDK4/6 Inhibitor Treatment Via Single-Agent Hormonally Based Regimen
Presentation delivered at the ninth-annual Metastatic Breast Cancer Research Conference in Park City, Utah
Benzinga · 09/14 15:28
Sermonix Pharmaceuticals Shares Details of First-Ever Known Durable Complete Clinical Response in a Metastatic ER+/HER2- Breast Cancer Patient With an ESR1 Mutation After Prior CDK4/6 Inhibitor Treatment Via Single-Agent Hormonally Based Regimen
Presentation delivered at the ninth-annual Metastatic Breast Cancer Research Conference in Park City, Utah Case was reported during Phase 2 study investigating efficacy of lasofoxifene, Sermonix’s lead investigational drug COLUMBUS, Ohio, Sept. 14, 2022 (G...
GlobeNewswire · 09/14 15:22
Ligand Pharmaceuticals' Lasofoxifene Shows Durable Complete Response in Breast Cancer Patient
Ligand Pharmaceuticals' Lasofoxifene Shows Durable Complete Response in Breast Cancer Patient
MT Newswires · 09/14 12:27
Ligand, Sermonix breast cancer drug lasofoxifene fails to show 'statistical significance' in trial
Sermonix Pharmaceuticals said lasofoxifene ...
Seekingalpha · 09/13 15:11
BRIEF-Sermonix Announces Results Of Phase 2 Study Of Lasofoxifene Versus Fulvestrant
BRIEF-Sermonix Announces Results Of Phase 2 Study Of Lasofoxifene Versus Fulvestrant
Reuters · 09/13 13:34
Sermonix Pharmaceuticals Announces Results Of Phase 2 Study Of Lasofoxifene Vs. Fulvestrant In Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer and An ESR1 Mutation; All Endpoints Numerically Favored Lasofoxifene
COLUMBUS, Ohio, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated metastatic breast and
Benzinga · 09/13 13:15
More
About LGND
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company. It is focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. It has partnerships and license agreements with approximately 140 pharmaceutical and biotechnology companies and 400 programs are in various stages of commercialization, development, or research and are fully funded by its collaboration partners and licensees. The Company's OmniAb business segment is focused on enabling the discovery of therapeutic candidates for its partners by pairing antibody repertoires generated from its proprietary transgenic animals with its OmniAb business platform screening tools. The Company's Ligand core business segment is a biopharmaceutical business focused on developing or acquiring technologies that help pharmaceutical companies deliver and develop medicines. The OmniAb platform creates and screens diverse antibody pools and is designed to identify optimal antibodies.

Webull offers kinds of Ligand Pharmaceuticals Inc. stock information, including NASDAQ:LGND real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LGND stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LGND stock methods without spending real money on the virtual paper trading platform.